Europe Cell Therapy Market Size, Share, and COVID-19 Impact Analysis, By Therapy Type (Allogeneic Therapies, Autologous Therapies, Stem-Cell Therapies, Non-Stem Cell Therapies, and Others), By Therapeutic Area (Oncology, Cardiovascular Disease, Musculoskeletal Disorders, Dermatology, and Others), and Europe Cell Therapy Market Insights, Industry Trends, Forecast to 2035.

Europe Cell Therapy Market Insights Forecasts to 2035

• The Europe Cell Therapy Market Size Was Estimated at USD 1.62 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of Around 27.1% from 2025 to 2035
• The Europe Cell Therapy Market Size is Expected to Reach USD 22.65 Billion by 2035

According to a research report published by Spherical Insights & Consulting, The Europe Cell Therapy Market Size Is Anticipated To Reach USD 22.65 Billion By 2035, Growing At A CAGR of 27.1% From 2025 to 2035. The market is driven by the region has seen strong grants for translational research, a surge in the need for regenerative therapies and an increase in chronic and ageing-related degenerative diseases.

Market Overview

Cell therapy is the application of live human cells (autologous, allogeneic, and engineered cell populations) in the clinics for restoration, repair, and replacement of damaged tissues, as well as the modulation of pathological immune responses. Cell therapies are living drugs and, therefore, their production involves complex logistics, a very strict identity requirement, and sometimes even individual patient batch production. CAR-T cell therapies are vital for blood cancers, and there are still trials going on for solid tumors. Stem cells are used in the treatment of heart disease, diabetes, autoimmune disorders, and gastrointestinal issues.

In July 2025, the European Commission declared a future viewpoint along with its new ambition to be a worldwide life sciences leader, which was supported by the introduction of an EU Biotech Act proposal.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended ExCellThera's Zemcelpr favorably, and the European Commission gave the drug conditional marketing authorization for adult patients with hematologic malignancies requiring stem cell transplant but having no compatible donor. The treatment involves the fusion of the cord blood–derived stem cells that are expanded ex vivo through UM171, a patented small compound promoting stem cell self-renewal, with cells from the same unit that remain unchanged.

EASYGEN intends to boost patient access to treatment through hospital workflow enhancement and has received $8 million in EU funding from the Innovative Health Initiative. The support of multi-partner initiatives for speeding up the development of cell and gene therapy for rare and genetic diseases, and the time government announcements concerning modern biotech solutions are increasing.

Report Coverage

This research report categorizes the market for the Europe Cell Therapy Market Size based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe cell therapy market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe cell therapy market.

Driving Factors

The Cell Therapy Market in Europe is driven by continuous public financial support for scientists and researchers. The UK Medical Research Council granted the cell and gene therapy catapult 90 million pounds to speed up processing and get ready for regulatory approval. The increasing number of chronic degenerative diseases in Europe is a major reason for the clinical use of regenerative cell-based treatments. Neurodegenerative diseases and, even more urgently, Alzheimer's Disease International claims that 9.1 million Europeans are suffering from dementia, which is forecasted to double by the year 2050.

Restraining Factors

The Cell Therapy Market in Europe is restrained by the production of cell therapies is a very complex process that includes several different stages, such as upgrading and checking the quality of the cells, which all need the use of special machines and adhering to strict rules that will keep the cells alive and safe. Besides, every single person who can be treated by these methods, together with the rapid processing time, limits the products to be made in large quantities, thus requiring very good transportation, such as temperature-controlled carriage, to ensure the delivery takes place at the right time.

Market Segmentation

The Europe cell therapy market share is categorised into therapy type and therapeutic area.

• The autologous therapies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Europe Cell Therapy Market Size is segmented by therapy type into allogeneic therapies, autologous therapies, stem-cell therapies, non-stem cell therapies, and others. Among these, the autologous therapies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The cell therapy market in 2024 will be mainly composed of autologous cells, which will have about 62% share due to their numerous advantages like lower rejection challenges, more precise treatment choice, better engraftment, and less ethical issues. Autologous cell therapy consists of taking the cells from a patient and then altering them in a lab outside the body using gene editing or other methods.

• The oncology segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on therapeutic area, the Europe Cell Therapy Market Size is segmented into oncology, cardiovascular disease, musculoskeletal disorders, dermatology, and others. Among these, the oncology segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The cell therapy market accounted the 48% in 2024, with cell therapies being the main reason for this transformation in cancer treatment. The novel and targeted approaches that the disease has to face are the very ones that these therapies provide. This new and not to mention very effective way of dealing with the disease has given hope in identifying the right intervention that will work well among the various categories of tumors; pediatric, hematologic, solid cancers and genetic types.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe Cell Therapy Market Size, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                                                                      

• TC BioPharm
• Cellin Technologies
• 3P Biopharmaceuticals
• Cell-Easy
• Cellpoint
• Treefrog Therapeutics
• Tigen
• Selexis
• Ixaka
• Novartis
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In October 2025, MeiraGTx Holdings plc, a vertically integrated, clinical-stage genetic medicines company, announced that the Company will exhibit two posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, which is being held from October 7-10, 2025, in Seville, Spain.

In August 2025, Eisai Co., Ltd. and Biogen Inc. announced that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI” had been launched in Austria in August 2025 and will be launched in Germany in September 2025. LEQEMBI received the European Commission (EC) approval in April 2025 as the first therapy that targets an underlying cause of Alzheimer’s disease (AD).

In February 2025, Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced that the European Commission had provided a positive opinion from the European Medicines Agency’s Committee for Advanced Therapies for OCU400 Advanced Therapy Medicinal Product classification.

Market Segment

This study forecasts revenue at the Europe, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Europe Cell Therapy Market based on the below-mentioned segments:

Europe Cell Therapy Market, By Therapy Type

• Perfume & Cosmetics
• Wine & Spirits
• Fashion & Accessories
• Tobacco Products
• Electronics & Gifts
• Others

Europe Cell Therapy Market, By Therapeutic Area

• Oncology
• Cardiovascular Disease
• Musculoskeletal Disorders
• Dermatology
• Others